4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
SELLAS Life Sciences Group, Inc. (SLS) operates in the Biotechnology industry and is headquartered in New York, United States with about 13 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, SLS reported $0M in revenue and ($27M) in net income.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $1M | — |
| Gross Profit | — | — | $0M | $1M | $7M |
| Operating Income (EBIT) | ($28M) | ($32M) | ($38M) | ($32M) | — |
| Net Income | ($27M) | ($31M) | ($37M) | ($41M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($9M) | ($8M) | ($7M) | ($7M) | ($6M) |
| Net Income | ($8M) | ($8M) | ($7M) | ($7M) | ($6M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $78M | $19M | $6M | $21M | — |
| Total Liabilities | $8M | $10M | $14M | $16M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SLS viewer.
About TickerBase · Data methodology & sources